A detailed history of Efg Asset Management (North America) Corp. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Efg Asset Management (North America) Corp. holds 108,413 shares of HALO stock, worth $5.09 Million. This represents 1.06% of its overall portfolio holdings.

Number of Shares
108,413
Previous 140,269 22.71%
Holding current value
$5.09 Million
Previous $7.34 Million 15.55%
% of portfolio
1.06%
Previous 1.3%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$51.3 - $64.42 $1.63 Million - $2.05 Million
-31,856 Reduced 22.71%
108,413 $6.2 Million
Q2 2024

Jul 25, 2024

BUY
$37.81 - $52.4 $6,805 - $9,432
180 Added 0.13%
140,269 $7.34 Million
Q1 2024

May 13, 2024

BUY
$33.68 - $41.95 $315,143 - $392,526
9,357 Added 7.16%
140,089 $5.7 Million
Q4 2023

Feb 08, 2024

SELL
$33.32 - $42.1 $233,473 - $294,994
-7,007 Reduced 5.09%
130,732 $4.83 Million
Q3 2023

Nov 02, 2023

SELL
$36.46 - $44.03 $140,079 - $169,163
-3,842 Reduced 2.71%
137,739 $5.26 Million
Q2 2023

Jul 28, 2023

BUY
$30.28 - $38.74 $790,641 - $1.01 Million
26,111 Added 22.61%
141,581 $5.11 Million
Q1 2023

Apr 27, 2023

SELL
$32.86 - $55.7 $299,091 - $506,981
-9,102 Reduced 7.31%
115,470 $4.41 Million
Q4 2022

Feb 03, 2023

SELL
$40.06 - $59.44 $1.05 Million - $1.56 Million
-26,183 Reduced 17.37%
124,572 $7.09 Million
Q3 2022

Oct 28, 2022

SELL
$38.53 - $51.78 $817,375 - $1.1 Million
-21,214 Reduced 12.34%
150,755 $5.96 Million
Q2 2022

Aug 04, 2022

SELL
$37.35 - $48.3 $4.57 Million - $5.91 Million
-122,444 Reduced 41.59%
171,969 $7.57 Million
Q1 2022

Apr 26, 2022

SELL
$31.97 - $41.06 $39,738 - $51,037
-1,243 Reduced 0.42%
294,413 $11.7 Million
Q4 2021

Feb 18, 2022

BUY
$31.82 - $40.75 $9.41 Million - $12 Million
295,656 New
295,656 $11.9 Million

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.54B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Efg Asset Management (North America) Corp. Portfolio

Follow Efg Asset Management (North America) Corp. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Efg Asset Management (North America) Corp., based on Form 13F filings with the SEC.

News

Stay updated on Efg Asset Management (North America) Corp. with notifications on news.